Hepion Pharmaceuticals Inc
NASDAQ:HEPA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hepion Pharmaceuticals Inc
EPS (Diluted)
Hepion Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
|
EPS (Diluted)
-$107
|
CAGR 3-Years
-126%
|
CAGR 5-Years
3%
|
CAGR 10-Years
34%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$8
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$22
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Hepion Pharmaceuticals Inc
Glance View
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey and currently employs 20 full-time employees. The company went IPO on 2014-02-07. The firm is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company’s cyclophilin inhibitor, CRV431, offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The firm has created an AI platform, called AI-POWR, which stands for Artificial Intelligence Precision Medicine Omics World database access and Response and clinical outcomes. The platform helps to identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups.
See Also
What is Hepion Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-107.4
USD
Based on the financial report for Dec 31, 2024, Hepion Pharmaceuticals Inc's EPS (Diluted) amounts to -107.4 USD.
What is Hepion Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
34%
Over the last year, the EPS (Diluted) growth was -771%. The average annual EPS (Diluted) growth rates for Hepion Pharmaceuticals Inc have been -126% over the past three years , 3% over the past five years , and 34% over the past ten years .
